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Abstract 
Parkinson’s disease is a neurologic disease characterized by both motor and non-motor 
symptoms, but also by nerve cell loss in the brain. A hallmark characteristic of Parkinson’s 
disease is the presence of Lewy bodies which are abnormal aggregates of protein in nerve 
cells, and which major component is the α-synuclein. It is believed that this protein plays a 
crucial role in Parkinson’s disease development. Alzheimer’s disease is the most common 
cause of dementia in the elderly, affecting more than 24 million people around the globe. 
The initial symptoms of this disease include loss of memory and orientation, as well the 
presence of two pathological features: the presence of neurofibrillary tangles and amyloid 
plaques, which major component is the amyloid-β peptide. Despite the advances in the 
investigation of new therapies for this disease, current treatment available continues focusing 
on reducing the symptoms of the patient and not on the reversal of the disease. Moreover, 
the blood-brain barrier remains the major obstacle to the development of new therapies due 
to its restrictions, limiting approximately 98% of the small molecules. Through the use of 
nanoparticles targeted to the brain and where the drug can be encapsulated, the crossing of 
the blood-brain barrier becomes possible by drugs that otherwise were not able. Therefore, 
the drug is slowly released in the brain, increasing the efficiency of the therapeutic drug and 
decreasing peripheral and/or systemic toxicities that could arise from its systemic use.  
This study aimed to develop a targeted therapeutic system for intravenous 
administration, using solid lipid nanoparticles, a biocompatible and biodegradable colloidal 
delivery system, widely researched for medical applications, with a propose of drug delivery 
system. The nanoparticles were encapsulated with resveratrol and grape’s extracts, the main 
source of natural resveratrol, to be used as therapeutic agents in the combat against 
Parkinson’s disease and Alzheimer’s disease. The lipid nanoparticles were also functionalized 
with an OX-26 antibody that specifically targets the transferrin. The nanoparticles where 
characterized morphologically by size, zeta potential and entrapment efficiency. Particle size 
was in the desired range (150-200nm), their entrapment efficiency percentage achieved the 
90%, but the zeta potential was lower than expected, still the nanoparticles remain stable for 
at least 2 months. When conjugated with the antibodies, the nanoparticles lost their stability, 
aggregating and resulting in a higher nanoparticle size.  
Furthermore, nanoparticle morphology was analysed by transmission electron microscopy, 
allowing the observation of the spherical shape of the nanoparticles, but also small 
aggregates in some of the samples. The interaction with α-synuclein and amyloid-β peptides 
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was also studied with Thioflavin T fluorescent assays and the ability of delaying the 
aggregation of these peptides could be confirmed, demonstrating that the nanoparticles 
synthesized are promising candidates for the treatment of both Parkinson’s and Alzheimer’s 
disease.  
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Resumo 
A doença de Parkinson é uma doença neurológica caracterizada tanto por sintomas 
motores como não motores, mas também pela perda de células nervosas no cérebro. A 
característica principal desta doença é a presença de corpos Lewy que são agregados 
anormais de proteínas nas células nervosas, e cujo principal componente é a α-sinucleína. 
Pensa-se que esta proteína desempenha um papel crucial no desenvolvimento da doença de 
Parkinson. A doença de Alzheimer é a causa mais comum de demência na idade avançada, 
afetando mais de 24 milhões de pessoas em todo o mundo. Os sintomas iniciais da doença 
incluem perda de memória e dificuldade na orientação, bem como a presença de duas 
características patológicas: a presença de emaranhados neurofibrilares e placas de amilóide, 
cujo principal componente é a amilóide-β. Apesar dos avanços na investigação de novas 
terapias, os tratamentos atuais continuam a focar-se na redução dos sintomas do paciente e 
não na reversão da doença. Além disso, a barreira hematoencefálica continua a ser o maior 
obstáculo ao desenvolvimento de novas terapias devido às suas características limitantes, 
bloqueando aproximadamente 98% das moléculas pequenas. Através do uso de nanopartículas 
direcionadas para o cérebro onde o fármaco possa ser encapsulado, a passagem através da 
barreira hematoencefálica torna-se possível para fármacos que de outra forma não seriam 
capazes de o fazer. Desta forma, o fármaco é libertado lentamente no cérebro, aumentando 
a sua eficiência e diminuindo efeitos tóxicos periféricos e/ou sistémicos que poderiam ocorrer 
do seu uso sistémico. 
Este estudo teve como objetivo o desenvolvimento de um sistema terapêutico direcionado 
para administração intravenosa utilizando nanopartículas lipídicas sólidas, que consiste num 
sistema coloidal biocompatível e biodegradável de entrega de fármacos e que é amplamente 
estudado para aplicações médicas com o objetivo de entregar fármacos. Resveratrol e 
extratos de uva, a fonte natural principal de resveratrol, foram encapsulados nestas 
nanopartículas para serem utilizados como agentes terapêuticos no combate contra as 
doenças de Parkinson e Alzheimer. As partículas foram também funcionalizadas com o 
anticorpo OX-26 que se liga especificamente à transferrina. As nanopartículas foram 
caracterizadas morfologicamente pelo tamanho, potencial zeta e eficiência de 
encapsulamento. O tamanho das nanopartículas estava dentro da escala desejada (150-200 
nm) e a sua eficiência de encapsulação alcançou os 90%, mas o seu potencial zeta foi mais 
baixo que o esperado, mas mesmo assim, as partículas continuaram estáveis pelo menos 
durante 2 meses. Quando conjugadas com os anticorpos, as nanopartículas a sua estabilidade 
diminuiu, agregando e resultando em nanopartículas de maior tamanho. 
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Além disso, a morfologia das nanopartículas foi analisada por microscopia eletrónica de 
transmissão, permitindo a observação da sua forma esférica, mas também de pequenos 
agregados em algumas amostras. A interação com os péptidos α-sinucleína e amilóide-β foi 
estudada com ensaios de fluorescência de Tioflavina T e a capacidade de atrasar a agregação 
destes péptidos foi confirmada, demonstrando que as nanopartículas sintetizadas são 
candidatos promissores para o tratamento das doenças de Parkinson e Alzheimer. 
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Chapter 1  
Introduction 
1.1 - Motivation 
Over the last years, the world’s population has been aging at an accelerating rate. 
Combining this with the increase of the life expectancy in industrialized countries, it is 
possible to understand the burden of neurodegenerative diseases today.  
Parkinson’s disease (PD) is the second most common neurodegenerative disorder [1]. It is 
characterized by both motor and non-motor symptoms, but also by nerve cell loss in the 
brain. A hallmark characteristic of Parkinson’s disease is the presence of Lewy bodies which 
are abnormal aggregates of protein in nerve cells, and which major component is the α-
synuclein [2]. It is believed that this protein plays a crucial role in Parkinson’s disease 
development. Another neurodegenerative disease is the Alzheimer’s disease (AD), the most 
common cause of dementia in the elderly, affecting more than 24 million people around the 
globe. As PD, the most influential risk factor is the age. The initial symptoms of AD involve 
loss of memory and orientation, as well the presence of two pathological features: the 
presence of neurofibrillary tangles and amyloid plaques, which major component is the 
amyloid-β peptide [3]. 
Even though the advances in the investigation of new therapies for PD and AD, current 
treatments available continues focusing on reducing the symptoms of the patient and not on 
the reversal of the disease. One factor for this to happen it the existence of the blood-brain 
barrier (BBB), which is responsible for the restriction of the majority of therapeutic drugs, 
when intravenously administrated, to the central nervous system (CNS). It is also responsible 
for the dropout of relatively new drugs that have a good efficacy in vitro but cannot pass this 
strict barrier [4]. 
Nanomedicine was born from the fusion of nanotechnology with the need of drug delivery 
and studies how the drug administration, pharmacokinetics and pharmacodynamics are 
affected by the use of nano-sized materials [5]. The role of nanotechnology in the treatment 
of neurodegerative disease arises from the necessity to mask the physicochemical properties 
of the therapeutic drugs in order to have a longer blood-stream life and to be able to cross 
the BBB into the CNS. This can be achieved by encapsulation of the drug in a nanoparticle 
which can be made of different kinds of biomaterials. Lipid and polymeric nanoparticles are 
the two most used classes of nanoparticles used for drug delivery across the BBB, due to their 
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ability to reduce the common side effects of the current drugs through their encapsulation 
[4]. 
1.2 - Main objective 
In this context, the aim of the present work is to develop lipid nanoparticles loaded with 
therapeutic compounds for the treatment of PD and AD. The therapeutic compound chosen 
was the resveratrol, which is a biologically active substance found in plants and exhibits 
several health beneficial effects. One of these effects is neuroprotection in 
neurodegenerative disease, such as PD and AD [6]. Since it is present mainly in grapes, its 
extracts are a natural alternative to resveratrol, so they were also encapsulated into lipid 
nanoparticles. 
1.3 - Thesis organization 
The present dissertation is organized into five different chapters. The first chapter is the 
Introduction, and it is where the motivation and main objective of this research work are 
stated. The second chapter, State of the art, carries out an overview of the Parkinson’s and 
Alzheimer’s disease, the blood brain barrier and lipid nanoparticles, and also a review of the 
last studies on nanoparticles used for the treatment of both Parkinson’s disease and 
Alzheimer’s disease. The Materials and Methods chapter describes the list of materials used 
and all the methodologies applied during this work. Results and respective discussion are 
described in the Results and Discussion chapter. The last chapter, Concluding Remarks and 
Future Perspectives summarizes the work developed, presenting the main conclusions based 
on the results obtained, but also suggestions of possible future work that can be useful for the 
present project. Finally, in the Annex are included all the supplementary results.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2  
State of the Art  
2.1 - Parkinson’s disease 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder, after 
Alzheimer’s disease. It is estimated to affect 10-18% of the world population and has an 
annual incidence of 0.4-2%. There is also a rising prevalence with age and a higher incidence 
in the male population [1]. PD is an incurable and progressive disorder that is characterized 
by a chronic and progressive movement disorder with pigmented neuron degeneration in the 
substantia nigra, resulting in a decrease in nigrostriatal availability of the neurotransmitter 
dopamine [7]. In most cases, PD occurs as a sporadic type of disease (90-95%) with no 
apparent genetic linkage, but can also appear as a rare familial form (5-10%) [8, 9]. The 
average age of disease onset in PD is around 60 years, with a life expectancy of about 15 
years since diagnosis. Furthermore, the majority of early-onset patients (diagnosed under 40 
years old) have a positive family history of PD and long disease duration, while older patients 
(over the age of 70 years) tend to have shorter disease durations ( approximately 5 to 10 
years) and more rapid and severe disease progression [10, 11]. 
PD has two main neuropathological hallmarks. The first one is the degeneration of basal 
ganglia neurons, predominantly pigmented dopaminergic neurons of the substantia nigra pars 
compact of the midbrain [12, 13], and the second is the presence of α-synuclein positive 
intracytoplasmatic inclusions and axons known as Lewy bodies and Lewy neurites that are 
formed in the survival dopaminergic neurons [14]. Lewy bodies are cytoplasmic inclusions 
constituted by aggregated proteins. As mentioned before, the major component of Lewy 
bodies in sporadic PD is the α-synuclein, a 140 amino acid presynaptic protein. It is thought 
that this protein plays a crucial role in PD development [15]. Moreover, examination of PD 
brains identified the presence of neurofilaments and ubiquitin, changes in mitochondrial 
function, increased oxidative stress, lysosomal dysfunction, protein aggregation and impaired 
degradation, deposition of iron as well inflammation and glial activation [16, 17]. 
Until a few years ago, the aggregation of α-synuclein protein was thought to be 
modulated by point mutations associated with familial PD, various environmental factors, 
posttranslational modifications, and interaction with cellular membranes and different 
proteins [18]. Nevertheless, it was not known if genetic or epigenetic factors might perturb 
the metabolism, solubility, or interactions of the α-synuclein in sporadic PD and synuclein in 
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dystrophic neurites [13]. Nowadays, PD is considered to have a complex multi-hit etiology 
involving multiple influences including lifestyle, genetics (e.g. α-synuclein mutations) and 
environment (e.g. insecticide exposure) [19, 20]. In 2007, a dual-hit hypothesis for the 
progression of PD was proposed, suggesting that an external factor could initiate this 
pathogenesis by induction of the α-synuclein pathology, which moves along two potential 
paths to the midbrain. One of these paths begins due to the exposure in the olfactory bulb, 
while the other is caused by the exposure in the gastrointestinal tract. At some point, both of 
these pathways result in damage to the nervous system [21]. The progression of the PD is 
hypothesized to occur in a predictable pattern that begins in the caudal brainstem (dorsal 
motor nucleus of glossopharyngeal and vagal nerves) and olfactory bulb (anterior olfactory 
nucleus) (stage I), ascending to the pontine tegmentum (stage II), midbrain (stage III), 
mesocortex and allocortex (stage IV) and finally culminating in widespread neocortical 
involvement (stages V and VI) [22]. This progression is represented in Table 2.1. 
 
Table 2.1 - Parkinson’s disease stages by Braak (I to VI), and respective pathological disease’s 
progress and symptoms (emphasis on non-motor symptoms). Adapted from [23]. 
Stage I II III IV V and VI 
Pathology 
Enteric plexus, 
olfactory bulb, 
vagus nerve, 
cardiac 
sympathetic 
neurons, 
parasympathetic 
cholinergic 
dysfunction 
Locus 
coeruleus, 
reticular 
formation 
Amygdala, 
Meynert’s 
nucleus 
Substantia 
nigra 
Temporal 
mesocortex, 
allocortex, 
limbic 
circuit 
Widespread 
neocortical 
involvement 
Symptoms 
Constipation, 
dysautonomia, 
hyposmia,  
anxiety, 
urinary and 
erectile 
dysfunction 
Sleep 
disturbances, 
depression 
Unilateral tremor and 
bradykinesia,  
subclinical gait dysfunction, 
behavioural memory 
disorder 
Impulse 
control 
disorders, 
memory and 
emotional 
impairment 
Motor 
symptoms 
2.2.1 - α-Synuclein and Parkinson’s disease 
The α-synuclein protein is encoded by a single gene, the SNCA gene, which consists on 
seven exons located at the chromosome 4, and lacks both cysteine and tryptophan residues 
[18, 19]. Moreover the α-synuclein protein is small, soluble and highly conserved, with the 
predominant isoform being 140 amino acids long [24]. 
In 1997, after a mutation in α-synuclein gene was found to be associated with the familial 
cases of early-onset PD, and its aggregates were found to accumulate in  components of the 
neural perikaryal (Lewy bodies) and neuronal processes (Lewy neuritis), the interest of study 
this protein increased [18, 25].  
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A major effect of the α-synuclein mutation that leads to an alanine to threonine 
substitution at position 53 (A53T), is thought to be the promotion of the aggregation of α-
synuclein into fibrillar assemblies in nerve cells [13], resulting in the formation of Lewy 
bodies and Lewy neurites [26]. Due to this, the α-synuclein aggregation and Lewy bodies’ 
formation could be important in the etiology and pathogenesis of all cases of PD [13, 16].  
The abnormal accumulation of α-synuclein insoluble aggregates in neuronal cells that 
characterizes PD, is also related with other neurodegenerative conditions which are 
collectively termed as synucleinopathies, such as dementia with Lewy bodies and multiple 
system atrophy, as well as rare disorders such as various neuroaxonal dystrophies [11, 27].  
 
Localization of α-synuclein 
α-Synuclein in its native, aggregated and supposed pathological (oligomeric, 
phosphorylated) form has been found in a variety of tissues from both living and deceased PD 
patients including cerebrospinal fluid (CSF), blood (erythrocytes and platelets), urine, saliva, 
gastrointestinal tract, vagus nerve, sympathetic and stellate ganglia, cutaneous autonomic 
nerves, and submandibular gland [19, 24, 28]. 
Thus, this protein is abundantly expressed in the nervous system, comprising 1% of total 
cytosolic protein. In presynaptic terminals α-synuclein is present in high concentration in 
close proximity, but no within, synaptic vesicles, and it is found in both soluble and 
membrane-associated fractions of the brain [29].  
 
Structural properties and function of α-synuclein 
The α-synuclein protein, in aqueous solution, does not have a defined structure, being an 
intrinsically disordered protein (hence the term natively unfolded protein) at neutral pH, but 
compacter than a random coil (Figure 2.1: left image). The intrinsically disordered proteins 
are characterized by a unique combination of low overall hydrophobicity, low sequence 
complexity and high net charge. Thus existing as dynamic and highly flexible structural 
ensembles, either at the secondary or at the tertiary structure level [18]. 
The structure of α-synuclein (Figure 2.1: right image) can be divided into three different 
regions: an amino terminus (residues 1–60) which contain four 11-amino acid imperfect 
repeats (coding for amphipathic α-helices) with a conserved motif (KTKEGV), a central 
hydrophobic region (residues 61–95), containing the hydrophobic and highly amyloidogenic 
Non-beta-amyloid component (NAC) region and three additional KTKEGV repeats, which 
confers the β-sheet potential, and finally, a carboxyl terminus (residues 96–140), containing 
the highly enriched in acidic residues and the prolines C-terminal region, that confers an 
highly negative charge. While, the first two regions comprise a membrane-binding domain, 
the C-terminal tail is thought to contain protein–protein and protein–small molecule 
interaction sites [18, 27].  
The α-synuclein protein is a member of the synuclein family of proteins, which also 
include β- and γ-synuclein. What structurally differentiates α-synuclein from the other family 
members is the NAC region. All three members of the family are predominantly neuronal 
proteins that under physiological conditions localize preferentially to presynaptic terminals 
[30]. 
The α-synuclein might have several functions, which include synaptic vesicle release and 
trafficking, fatty acid binding and physiological regulation of certain enzymes, transporters, 
6 State of the Art 
 
 
 
and neurotransmitter vesicles, as well as roles in neuronal survival. Moreover, α-, β-, and γ-
synucleins are important contributors to long-term operation of the nervous system. 
Furthermore, α-synuclein can interact with at least 30 proteins, having and important role in 
cell signalling [18]. 
 
 
Figure 2.1 – Representation of the α-synuclein structure taken from the Protein Databank ID: 1XQ8 
(left), and schematic structure of α-synuclein protein (right) [27]. 
Conformational behaviour of α-synuclein 
The α-synuclein protein has the ability to adopt different conformations depending on the 
environment, and interacts easily with others ligands, such as lipids [31]. Thus, the 
conformational behaviour of the α-synuclein protein is determined by its relatively low 
hydrophobicity and high net charge nature. Therefore, alterations in the environment can 
lead to an increase in its hydrophobicity and/or decrease in the net charge, inducing a partial 
folding of the protein [18].  
As a result, α-synuclein can adopt a number of different conformational states that 
depends on several conditions and cofactors. These conformational states include the 
formation of α-helical structures by binding to negatively charged lipids such as phospholipids 
present on cellular membranes, and it consists in a partially-folded state that is crucial in the 
aggregation and fibrillation, formation of various oligomeric species, and fibrillar and 
amorphous aggregates; and of β-sheet-rich structures on prolonged periods of incubation [27]. 
Furthermore, the partial folding might lead to α-synuclein self-association into 
amyloidogenic conformations, which is facilitated by the formation of solvent-exposed 
hydrophobic clusters on the surface of a partially folded protein as a consequence of an 
increase in concentration, a decrease in pH, an increase in temperature, an addition of 
amphipathic molecules (e. g. various agrochemicals, such as herbicides or pesticides), an 
addition of metal ions and other small charged molecules, interaction with charged 
biopolymers, interaction with other proteins, interaction with membranes, and immersion of 
a protein into a crowded environment [18]. 
Aggregation potential of α-synuclein 
The α-synuclein protein forms amyloid fibrils which can be divided in two structural 
classes: fibrils derived from folded proteins (β-sheet rich), and fibrils derived from 
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intrinsically disordered proteins. Amyloid fibrils are formed from folded proteins by either the 
refolding mechanism or by a gain-of-interaction model. In the refolding mechanism, proteins 
are converted from native structures to fibrils by initially unfolding, and then refolded into a 
secondary structure that is rich in β-sheets. The fibrils that are formed in this way are stable 
due to backbone hydrogen bonding, rather than side chain-side chain interactions. All of 
these native-like proteins are rich in β-structure, and as a result form fibrils with minimal 
alterations to their native structures [18].  
The formation of α-synuclein fibrils occurs in a nucleation-dependent manner, where the 
rate-limiting step is the spontaneous formation of small metastable oligomeric intermediates 
that results from partial folding and aggregation of unstructured α-synuclein, and exists in 
rapid equilibrium with its monomeric form. After, fibrils grow by a “dock and lock” 
mechanism, where monomers initially bind to the exposed regions of a fibril in a reversible 
manner. This is followed by an irreversible re-organization of the fibril surface, which 
generates the most optimal surface area for further fibril growth. Thus, the formation of 
oligomers is also a highly ordered process that involves an intrinsic rate-limiting lag phase. 
Nevertheless, a wide range of amyloidogenic proteins have been shown to assemble into 
common oligomeric and fibrillar conformations. This fact suggests that amyloid misfolding is 
largely mediated by peptidebackbone interactions, and not by interactions of the side groups 
[18]. 
The α-synuclein protein aggregation can take place e in the cytoplasm or inside the 
neurons, in association with the cellular membrane, and it is represented in Figure 2.2.  
 
 
Figure 2.2 – Mechanisms of α-synuclein aggregation and propagation. Image from [32]. 
Structure of the oligomers formed 
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There is at least three structural classes of amyloid oligomers (prefibrillar, fibrillar and 
annular) that are formed depending on the environmental conditions. Since α-synuclein 
belongs to a class of intrinsically disordered amyloid proteins it forms fibrils by converting 
either all or part of the previously unstructured polypeptide into well-defined, β-sheet rich 
secondary structures. The α-synuclein fibrils are composed of several protofilaments 
containing a cross-β structure in which β-strands are arranged in parallel, and the β-sheets 
are in-register with highly ordered amino acid side chain patterns exposed on the surface of 
the β-sheets. Furthermore, the side-chains protruding from the two β-sheets of the cross-β 
spine interdigitate in a self-complementary manner to give rise to highly ordered structures 
known as steric zippers [18].  
The α-synuclein fibrils can exhibit differences in the structure in consequence of 
variations in the folding of the β-sheets, differences in the molecular packing between sheet 
interfaces, or interactions of side chains with the environment. However, at the molecular 
level, fibrils and aggregates of α-synuclein have a five-layered parallel, inregister β-sheets 
core that consists of a five-layered β-sandwich [33]. Still, it is not clear whether they are 
parallel or antiparallel sheets (i.e. the initial α-synuclein oligomers may adopt an antiparallel 
structure whereas the fibrils are mostly parallel β-sheets) [34].  
The structural of the oligomers is translated to variability in cytotoxicity and biological 
activity [18]. Moreover, their ability to induce aggregation provides a molecular basis for the 
heterogeneous group of synucleinopathies caused by α-synuclein aggregation [35].  
Propagation of α-synuclein aggregates 
Recent findings hypothesize that amyloids associated with neurodegenerative diseases 
spread in a prion-like fashion [35]. Similarly to the self-propagating mechanism of infectious 
prion proteins, misfolded α-synuclein assemblies seed the aggregation of monomeric α-
synuclein in vitro and spread in a nucleation-dependent seeding mechanism from one cell to 
another in cell cultures and animal models. Furthermore, Lewy bodies and Lewy neurites 
have been shown to spread from the brain of patients developing PD to grafted neuronal cells 
[18]. The mechanism of α-synuclein oligomers and monomers propagation between cells is 
represented on Figure 2.2 and it can occur via endocytosis, direct penetration, trans-synaptic 
transmission or through membrane receptor [36].  It has been verified that Lewy bodies and 
Lewy neurites first appear in the dorsal motor of the vagal nerve in the brainstem and 
anterior olfactory structures, then spread stereotypically to large parts of the brain, following 
defined patterns as referred before. Thus, it is considered that the pathology begins first at 
the olfactory bulb and the dorsal vagal nucleus and gradually follows an ascending course, 
culminating in widespread α-synuclein pathology at the later stages, involving cortical 
regions, whereas the substantia nigra is only affected in stage 3 of this scheme [22]. Despite 
this hypothesis does not explain the absence of clinical symptoms in subjects who on autopsy 
have widespread α-synuclein pathology, it appears to hold up for the majority, but not all, of 
cases examined [37]. 
The potential pathogenic effects of α-synuclein 
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During the aggregation of the α-synuclein occurs the formation of metastable oligomer 
intermediates of α-synuclein that are considered to be the disease-associated species of the 
protein [18]. However, there is some inconsistency about which is the major neurotoxic 
species, the oligomers and/or the fibrils [18, 38]. 
There are three major classes of the neurotoxic mechanisms of α-synuclein and its 
aggregates: mechanical disruption of cellular compartments/processes, toxic gain of function, 
and toxic loss of function. Permeation of cellular membranes is considered to be the main 
neurotoxic mechanism, and it is based on the capacity of α-synuclein oligomers binding to 
lipid membranes and to disrupt membrane bilayers, but also because certain oligomeric forms 
were shown to penetrate membranes, leading or not to the formation of pore-like channels, 
and consequently cell death. Moreover, the impairment of α-synuclein degradation via 
proteasome inhibition by the aggregated species and copper-dependent generation of 
reactive oxygen species (ROS) have also been proposed as possible neurotoxic mechanisms of 
the α-synuclein aggregates. It is hypothesized that the α-synuclein-related neurotoxicity 
might arise from a loss of function [18]. On Figure 2.3 is represented both mechanism of α-
synuclein aggregation and toxicity model, where both oligomers and amyloid fibrils contribute 
to neurotoxicity (e.g. oxidative stress, protein sequestration, disruption of axonal transport, 
synaptic dysfunction, inhibition of ubiquitin-dependent proteasome (UPS) system and 
mitochondrial dysfunction). Here it is also represented the control systems (phagosomes, 
lysosomes and proteasomes) that prevent or reverse protein misfolding or eliminate misfolded 
proteins which, at some point of the disease, are overwhelmed by α-synuclein oligomers, thus 
contributing the toxicity effects [38].  
 
 
Figure 2.3 – Mechanism of α-synuclein aggregation and hypothetical model of the α-synuclein toxicity. 
Image from [38]. UPS: ubiquitin-dependent proteasome system. 
Interaction of α-synuclein with membranes 
The α-synuclein protein has several structural features that allows binding with synthetic 
vesicles containing acidic phospholipids and to cellular membranes. These features comprises 
several class A2 lipid-binding helices contained in the α-synuclein (distinguished by clustered 
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basic residues at the polar–apolar interface that are positioned ±100° from the centre of 
apolar face), a predominance of lysines relative to arginines among the basic residues, and 
several glutamate residues at the polar surface [18]. 
In presynaptic termini, monomeric α-synuclein exists in a tightly regulated equilibrium 
between free and membrane- or vesicle-bound states, being estimated that approximately 
15% of α-synuclein is membrane-bound within the synaptic termini. Thus, the inhibition of 
lipid oxidation by α-synuclein may be a physiological function of the protein [18]. 
2.2.2 - Parkinson’s disease-related mutations 
There is a small fraction of PD patients who have a familial form of PD with an autosomal-
dominant pattern of inheritance. Furthermore, it has been identified three point mutations in 
the SNCA gene encoding for α-synuclein on patients with familiar PD, leading to A53T, A30P, 
and E46K amino acid changes (Figure 2.1: right image). These mutations are all associated 
with autosomal-dominant PD, however, the distribution of the pathology at the cellular and 
molecular level is different in each case [27].  
These three PD-related point mutations do not affect the global structure of human α-
synuclein monomer. While the A30P mutation strongly attenuates the helical propensity that 
is found in the N-terminal region of the wild type α-synuclein, the A53T mutation applies a 
more modest influence on local structural propensity, resulting in a slightly enhanced 
preference for extended conformations in a small region around the site of mutation. The 
E46K mutation resulted in subtle changes in the conformation of the monomeric protein and 
enhanced the contacts between N- and C-termini of the protein. Moreover, the A30P 
mutation promoted α-synuclein oligomer formation, while A53T and E46K mutations promoted 
fibrillation. Thus, all three PD-related mutations of α-synuclein alter its secondary structure 
and promote its aggregation [18]. 
2.2.3 - Classic Parkinson’s disease therapy challenges 
Over the years, there has been a massive progress in the treatment of PD, however 
Levodopa (L-dopa) still is the gold standard for controlling PD symptoms. The therapy of each 
patient is individualized and several drugs are currently available. Besides L-dopa, there are 
other compounds that can substitute the L-dopa treatment or be simultaneous administered 
for an efficient therapy, like dopamine (DA) agonists, catechol-o-methyl-transferase (COMT) 
inhibitors, nondopaminergic agents, between others.  
However, oral L-dopa therapy can be affected by several interfering processes, leading to 
dose failures and long-term complications. The main situations interfering with the optimal 
delivery are the necessity to compete with ingested proteins for the amino acid transporters 
in the gastrointestinal tract and BBB, and the short half-life of L-dopa which is around 36 to 
96 minutes. In an advance stage of the disease, this can lead to fluctuating L-dopa 
concentration levels, and eventually, to fluctuations levels of DA derived from L-dopa. In an 
attempt to avoid these fluctuations, L-dopa must be administered as multiple doses, however 
this may not be enough [39]. Furthermore, a continuous intravenous infusion of L-dopa or DA 
is, at the moment, the only clinical method to abolish the motor fluctuations [40]. But the 
use of intravenous infusions is not practicable for a chronic therapy [39]. Currently, none of 
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the available treatments has been able to modify the natural neurodegenerative course of PD 
[41, 42]. On Table 2.2 are represented the main current drugs used for PD therapy, their 
clinical use as a monotherapy or adjuvant therapy and their advantages and disadvantages. 
Recent studies are focused on optimizing the delivery of L-dopa and other therapeutic 
drugs so the treatment of PD can be more efficient (more details in the further chapters). 
These studies are investigating how the BBB compromises the PD treatment and new drug 
delivery methods [7, 43].   
Two examples of new therapeutic compounds are the glial-derived neurotrophic factor 
(GDNF) and the urocortin. Both have a potential role in the PD treatment due to their 
neuroprotective and cytoprotectant effect, respectively. However, they have poor 
penetration of BBB and rapid blood clearance [44]. 
 
Table 2.2 – Current therapeutic approaches used in clinical [45]. 
Drug Class Drug Name Clinical Use Advantages Disadvantages 
Levodopa 
Sinemet, Parcopa, 
Atamet 
Monotherapy 
Increase levels of 
endogenous DA 
Motor fluctuations, 
dyskinesias 
Continuous 
Levodopa 
Intravenous bolus, 
Intravenous infusion, 
Intestinal L-dopa gel 
Monotherapy 
Decrease pulsatile 
DA levels, increase 
control on/off 
periods, decrease 
dyskinesia severity 
and duration, 
decrease non-
motor symptoms 
Large volumes 
required 
(intravenous), 
requires surgery 
and prosthetic 
device, mechanical 
problems 
Dopamine 
Agonists 
Piridedil, 
Pramipexole, 
Ropinirole, 
Rotigotine, 
Cabergoline, 
Pergolide 
Bromocriptine 
Monotherapy (on 
young patients), 
adjuvant therapy 
Increase levels of 
endogenous DA, 
decrease motor 
symptoms in early 
stages of disease 
Sedation, impulse 
control disorder, 
somnolence, 
edema 
MAO B Inhibitors 
Rasagiline, 
Selegiline, 
Safinamide 
Initial 
monotherapy, 
adjuvant therapy 
Well tolerated, 
decrease 
catabolism of DA 
Mild nausea, 
constipation, 
confusion 
COMT Inhibitors 
Entacapone, 
Tolcapone 
Adjuvant therapy 
Decrease 
metabolism of L-
dopa, decrease in 
daily dose of L-
dopa required, 
increase daily on 
time 
Dyskinesias, 
diarrhea, hepatic 
toxicity, dizziness, 
insomnia, nausea 
2.2 - Alzheimer’s disease 
Alzheimer’s disease (AD) is classified as the most common form of dementia, accounting 
with more than 80% of dementia cases worldwide [46]. The initial symptoms of AD are barely 
imperceptible since it is characterized by impaired short term memory and difficulties in 
acquiring new information [47]. As time goes by, the patient starts losing some cognitive 
functions, exhibit special disorientation and apathy and demonstrates difficulties in 
performing daily-basic activities, such as walking and dressing up. At the end, the patient 
experiences intense memory and cognition losses, leading to the immobility of the patient, 
who eventually succumb to respiratory difficulties (4-6 years after the initial diagnosis) [48]. 
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The advanced age is the major risk factor for developing AD, however the disease can also 
occur in very rare patients with 20-30 years old who have genetic mutations resulting in the 
formation of abnormal amyloid precursor protein (APP), presenilin 1, and presenilin 2 genes. 
Other factors that can influence the occurring of sporadic late-onset AD include mitochondrial 
defects, apolipoprotein genotype (ApoE4), insulin-dependent diabetes, environmental 
conditions, and diet [49, 50].  
The pathophysiological hallmarks that characterize AD are the presence of neurofibrillary 
tangles of hyperphosphorylated tau proteins and extracellular amyloid-β plaques (senile 
plaques) in the cortex and hippocampus, which are important areas for memory and learning 
[51]. Anatomically, AD begins in the entorhinal cortex of the brain and progresses to the 
hippocampus, posterior temporal and parietal neocortex, culminating with diffuse atrophy 
through the cerebral cortex due to the loss of neurons [50]. 
 
2.3.1 -  Amyloid-β and Alzheimer’s disease 
Amyloid-β is a 4 kDa amphiphilic peptide of 39 to 43 amino acids residues long and it is 
encoded by a gene localizes in chromosome 21 [52]. In AD patient’s brains, amyloid-β peptide 
is in a fibrillary state organized in a β-sheet structure and it is the main constituent of the 
plaque deposits, extracellular deposits of fibrils and amorphous aggregates of amyloid-β [53]. 
Moreover, there is evidence that the concentration amyloid-β aggregates has a direct relation 
with the degree of dementia of patients [54]. It is known that amyloid-β is localized in 
compartmental cellular organelles such as the endoplasmic reticulum and lysosomal network, 
however it has also been localized in the cytoplasm of brains of AD patients [55].  
Amyloid-β derives from the APP by sequential activities of β- and γ-secretases, and it is 
explained by the cascade hypothesis (Figure 2.4) [56]. The final products of this cascade are 
two sequences with a length of 40 or 42 amino acids [57]. Usually, the first one is produced 
more abundantly by cells and its aggregation kinetic rate is much lower than the other 
(amyloid-β(1-40) at 20 μM is stable for 8 days or more whereas amyloid-β(1-42) aggregates 
immediately) [58, 59]. The amyloid-β(1-42) is associated with AD due to have the most 
fibrillogenic sequence, having the ability of aggregating in a β-sheet conformation. However, 
there are other hypotheses that explain the molecular mechanism of AD, such as the 
cholinergic hypothesis. 
 
Amyloid cascade hypothesis 
The amyloid cascade hypothesis was formulated more than 20 years ago, and states that 
the amyloid-β fibril deposited in amyloid plaques initiates the formation of neurofibrillary 
tangle formation and several toxic events, leading to neuronal dysfunction, the main 
pathological effect of AD [60]. However, nowadays it is believed that amyloid-β oligomers, 
including protofibrils and prefibrillar aggregates, are the major toxic species in AD [61]. 
The APP is an integral transmembrane protein consisting in a single membrane-spanning 
domain, a large extracellular glycosylated N-terminus and a shorter cytoplasmic C-terminus, 
which is expressed in several tissues, however its concentration is higher in the synapses of 
neurons [62]. APP can be processed by two main pathways: non-amyloidogenic or 
amyloidogenic (Figure 2.4). The APP is normally cleaved by α-secretase on the non-
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amyloidogenic pathway and processed by β- and γ-secretases on the amyloidogenic pathway. 
This results in an imbalance between production and clearance of amyloid-β peptide. Then, 
amyloid-β spontaneously aggregate into soluble oligomers, fibrils and are eventually 
deposited in neurotoxic amyloid plaques. The formation of these toxic aggregates induce 
oxidative damage, promote tau hyperphosphorylation, results in toxic effects on synapses and 
mitochondria, and consequently causes the neuronal loss characteristic of AD [46, 63]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4 – Production of amyloid-β peptides. The APPP is cleaved by the β-secretase resulting on a 
secreted fragment if APP (sAPPβ) and a C-terminal fragment of APP (CTFβ). This last one is then cleaved 
by γ-secretase giving origin to a C-terminal fragment (CTFγ) and amyloid-β of various lengths (Aβ40 and 
Aβ42). The cleavage by α-secretase is not shown, however it cleaves the amyloid- β domain resulting in 
the production of amyloid-β. Image from [64]. 
 
Cholinergic hypothesis 
The cholinergic hypothesis defends that a dysfunctional cholinergic system is enough to 
result in memory deficit, a classical symptom of AD [65]. Moreover, AD patient’s brains 
exhibit degeneration of cholinergic neurons of the basal forebrain and a decline in cholinergic 
markers (choline acetyltransferase and acetyl cholinesterase) [66]. This hypothesis cannot 
explain the overall neuropathological features of AD, however it can elucidate an important 
part of AD’s cause.   
 
Aggregation process of amyloid-β 
Amyloid-β aggregates in a nucleation-dependent mechanism where partially folded forms 
of the peptide associate to each other, forming a stable nucleus. Other partially folded 
intermediates attach to this nucleus, and the aggregated peptide starts to form protofibrils. 
This chain process continues until the formation of highly structured and insoluble amyloid 
fibrils occurs. Mainly, the peptide’ transition process into fibrils consists of three phases: lag 
phase, elongation phase and plateau phase. The first one, the lag phase, consists in the 
unfolding of amyloid-β and in the formation of oligomers that include species with β-sheet 
structures which act as nucleus for the formation of mature fibrils. On the elongation phase, 
the fibril growths through the addition of monomers or oligomers to the nucleus. Finally, on 
the plateau phase, the maximum fibril growth is achieved [67, 68]. 
 
β-secretase 
γ-secretase 
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Figure 2.5 – Process of protein misfolding and fibrillization. The three phases of the transition process 
are also represented. Image from [64]. 
 
2.3.2 -  Alzheimer’s disease-related mutations 
There are three genes associates with early onset familial AD, as stated before: amyloid 
precursor protein (APP), presenilin 1, and presenilin 2. Studies have found several causative 
mutations of AD in the DNA of subjects who inherited AD, all of them were localized closely 
to the cleavage sites of β- or γ-secretases and lead to the production of amyloid-β(1-42) or to a 
change in the aggregation properties of amyloid-β [69, 70]. Mutations in presenilin 1 gene are 
responsible for the majority of the reported cases of familial AD (FAD), while presenilin 2 
gene mutations are relatively rare [69]. 
 
2.3.3 -  Current therapy  
Currently, no therapies have been clinically proven to effectively prevent the progression 
of AD yet, and the actual treatments do not affect the progression of the disease but only 
attenuate the symptoms of the disease, such as memory and cognitive function. The current 
therapies are based on cholinergic agents, namely inhibitors of acetylcholinesterase, due to 
the loss of cholinergic neurons [71]. These agents increase the acetylcholine’ levels to 
prevent the degradation of neurons, however with time the therapy becomes ineffective and 
the progressive loss of cholinergic neurons continues [49]. Furthermore, a vast majority of 
other potential AD targets are nearly unaffected by this treatment. The first drug based on 
this therapy was tacrine (Cognex®), but since it presented hepatotoxic effects, other drugs 
were developed, such as donepezil (Aricept®), rivastigme (Exelon®) and galantamine 
(Razadyne®, Reminyl®) [72]. 
Another therapeutic strategy includes the use of memantine, an N-methyl D-aspartate 
(NMDA) receptor antagonist. This drug acts by antagonizing glutamate at the NMDA receptor, 
improving the signal transmission, thus protecting against toxic damage in cholinergic 
 
     Lag Phase Elongation Phase 
Plateau 
Phase 
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neurons. This was the first drug to be approved by FDA for treatment in later stages of the 
disease [50]. 
Nevertheless, probably the best approach to overcome AD, it to reduce amyloid-β levels 
in the brain. Thus, several therapeutic strategies have been developed, and they aim to 
reduce or modulate amyloid-β production, including secretase inhibition and increase of 
amyloid-β clearance with amyloid vaccines, or to block the aggregation of amyloid-β with 
different agents, such as antibodies, breaker peptides, or small organic and natural molecules 
that selective bind and inhibit amyloid-β aggregation, consequently the inhibition of fibril 
formation is achieved [56, 73]. However, none of them have demonstrated an overall 
efficiency in stopping the disease progression or reverting the disease state and most of small 
molecules studied are weekly potent and poorly bioavailable, particularly to the brain. 
 
2.3 -   The blood brain barrier 
Brain drug delivery is still a challenge for the treatment of neurodegenerative diseases. 
The presence of the blood-brain barrier (BBB) prevents the delivery of most therapeutic 
agents, thus impeding an effective therapy.  
The BBB is an organized interface between peripheral circulation and the central nervous 
system (CNS) that is capable of responding to local changes and requirements and has a dual 
function as a barrier and a carrier. It protects the microenvironment of the CNS of fluctuation 
in the blood composition by blocking the transport of potentially toxic or harmful substances 
from the blood circulation to the brain, but it allows the crossing of energy substrates and 
nutrients by specific transport systems. Thus, this interface maintains the CNS homeostasis 
through the regulation of the ion balance and metabolites influx/efflux [74, 75]. 
The BBB is present in all brain regions expect in the regions that regulate autonomic 
nervous system and endocrine glands of the body [76]. 
2.4.1 - Structure and composition 
The BBB is composed by different cell types such as endothelial cells, perycites, 
astrocytes and microglial cells [77]. It consists of two membranes, the luminal and abluminal 
membranes of the capillary endothelium, which are separated by the endothelial cytoplasm 
(~200 nm) [78].  
Thigh junctions are present within the brain capillary endothelium, connecting adjacent 
endothelial cells, physically restricting the paracellular diffusion of ions and other polar 
solutes between endothelial cells [74]. Thus, limiting the passive diffusion to the brain of 
small lipophilic compounds of molecular weights bellow to 400 Da. Furthermore, the selective 
influx transport of hydrophilic compounds is permitted by transport proteins [4, 7]. 
The basal lamina is composed of type IV collagen, fibronectin, heparine sulfate and 
laminine. It functions as a charge and molecular weight barrier and interacts in complex ways 
with intergins to regulate permeability and cellular transport across the BBB. Pericytes are 
macrophage-like cells with smooth muscle properties that are embedded in the basal lamina 
around the blood vessels. They regulate permeability by release of vasoactive substances. As 
they decrease with age, there is an increase in the BBB permeability [79]. 
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2.4.2 - Transport mechanisms 
The transportation of molecules across the BBB can occur through different influx 
pathways. The transport mechanism by which a molecule is allowed to cross the BBB is 
dependent of its physicochemical properties. 
Lipid-mediated free diffusion 
A wide range of lipid-soluble molecules are capable of diffusion through the BBB, entering 
into the brain passively. This capability is correlated with the lipid solubility of the molecule. 
Base compounds (with a positive charge) are able to cross the BBB due to the interaction with 
negatively charged glycocalyx and phospholipid head groups of the membrane. Also, blood 
gases like oxygen and carbon dioxide diffuse across the BBB dependent of the concentration 
gradient [74]. Thus, the restriction of entry into the CNS is dependent on the molecule 
structural physicochemical properties, such as size (< 400-500 Da), charge, hydrogen bounding 
potential (< 8-10 hydrogen bonds with water) and lipophilicity [77, 78]. 
Carrier- or receptor-mediated transport 
Since the majority of the polar molecules cannot diffuse through cell membranes, cells 
express a large number of solute carriers, like choline and amino acid transporters, in the cell 
membrane. The orientation of these transporters results in preferential transport of 
substrates into or across the cell. Thus, the direction of the transport may be from blood 
circulation to the CNS or vice-versa [74]. 
Essential large molecules for the brain homeostasis, such as amino acids, hexoses, 
neuropeptides and proteins, cross the BBB through endocytotic mechanisms involving either 
receptor-mediated transcytosis (RMT) or adsorptive-mediated trancytosis (AMT).  RMT 
requires the binding of macromolecules to specific receptor on the cell, inducing endocytosis 
and subsequent transcytosis. On the other hand, AMT depends on the ligand electrostatic 
interaction with the surface charge of the endothelial cells for triggering endocytosis 
followed by transcytosis [74]. The main targets for RMT are transferrin receptor (also highly 
expressed in the liver, heart and other cells), insulin receptor (also highly expressed in 
adipose tissue, liver and muscle cells) and low-density lipoprotein (also highly expressed in 
the liver) [80]. 
 
ATP-binding cassette transporters 
The main role of the ATP-binding cassette transporters (ABC transporters), such as p-
glycoprotein (P-gp), is to function as an active flux pump that consumes ATP and transports 
potentially neurotoxic endogenous or xenobiotic molecules out of the CNS. Thus, these 
receptors have a vital neuroprotective and detoxifying function [74].  
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2.4.3 - A barrier to conventional therapy – methods to increase the 
transport 
The majority of the therapeutic drugs are not capable to reach the CNS in a 
therapeutically relevant concentration due to the relative impermeability of the BBB. 
Therefore,  BBB is the major impediment in the treatment of CNS disorders [81]. Nowadays, 
most of the new drug candidates to treatment of CNS disorders are large molecules that have 
poor pharmacokinetics and cannot cross the BBB. Additionally, approximately 98% of all small 
molecules are not transported across the BBB [78].  
Briefly, the restrict access to the brain is due to several characteristics of BBB, the 
existence of tight junctions that block the passage through the intercellular gap, the reduced 
rate of pinocytosis on the luminal side, the nonexistence of fenestrations, the enzymatic 
barrier (considered a second line of protection) and, finally,  due to the efflux transport 
system [80]. 
In order to overcome the limited access of therapeutic drugs to the brain, there are 
several methods to increase the transport from blood into the CNS [40, 82]. The most 
accepted is the physiological approach which takes advance of the receptor transcytosis 
capacity. In this non-invasive approach, drugs are modified to be recognizable by the nutrient 
transport system of BBB or are conjugated with ligands that recognize expressed receptors at 
the BBB. However, it can have some disadvantages, for instance the possible non-specific 
drug-receptor interactions in peripheral organs. Meaning that an high concentration of the 
drug with these target molecules can bound in other organs before they can reach the BBB 
[80]. Also, drugs can be modified to reduce the relative number of polar groups and increase 
the cross of it through the BBB. But, this can lead to loss of desired activity of modified drugs 
and extrusion of the drug outside with efflux pump due to increased drug lipophilicity [7]. 
Moreover, the inhibition of the efflux transporters can improve the treatment efficacy, but it 
can also result in intolerable adverse side effects after efflux inhibition [77].  
Other method is the invasive approach, which include several expensive technology that 
involve a high risk complications, such as intracerebroventricular infusion, convection 
enhanced delivery, disruption of BBB and polymeric or microchip systems. This method 
breaches the BBB mechanically in order to deliver drug to the brain [7, 77]. 
However, there is a promising way to cross the BBB and deliver drugs to targets within 
the CNS through the use of nanoparticles. It has already been demonstrated that the 
nanoparticles with their surface modified are capable to cross the BBB into the brain after 
intravenous administration via receptor-mediated pathways. 
2.4 - Nanoparticles as drug delivery systems for 
neurodegenerative disease’ therapy 
Nanoparticles are a class of drug delivery system which are able to target a certain part of 
the body for delivery of the therapeutic drug. The nanoparticle size vary in a range of 10 to 
1000 nm and can be constructed from various materials and carry an extensive variety of 
active compounds, such as chemotherapeutics, contrast agents, proteins and nucleic acids 
[7].   
18 State of the Art 
 
 
 
Nanoparticles allow the transportation of therapeutic drugs for PD and AD across the BBB, 
that otherwise was not possible, by masking the limiting physicochemical properties of these 
molecules through their encapsulation. Thus, it does not require the modification of the drug 
molecule, because the ability to cross the BBB is only dependent of nanoparticle’s properties 
[77]. Furthermore, the use of nanoparticles allows a reduction of the required doses by 
improving of the pharmacological and therapeutic properties of the drug, as well as a 
decrease peripheral and/or systemic toxicity [4, 7, 40].  
This system can be administered directly into the brain or they can be systemic delivery 
with a target action in the central nervous system [40]. The delivery across the BBB is mostly 
achieved through receptor-mediated endocytosis of the nanoparticles by brain capillary 
endothelial cells followed by transcytosis. The receptors available for targeting are, for 
example, lipoprotein, scavenger transferrin and insulin receptors [77].  
Since the ability to cross the BBB is not dependent of the chemical structure of the drug 
encapsulated, but of the physicochemical and biomimetic features of the nanoparticle, they 
must have several properties that make them suitable to be used for drug delivery across the 
BBB. These properties include nontoxicity, biodegradability, biocompatibility, non-
immunogenicity (unless it is targeting the monocytes/macrophages), stability in blood (no 
aggregation and dissociation), capacity of interacting with receptors present at the BBB, 
controllable drug releasing profiles, and ability to carry small molecules, proteins, peptides or 
nucleic acids [83, 84]. The nanoparticle must have a controlled size in order to have its 
properties uniform and consistent, but also to have to control of its biological fate [83]. 
Moreover, the nanoparticle size have influence on the endocytotic uptake mechanism. 
Commonly, nanoparticles with a size below to 200 nm are up taken by clathrin-mediated 
endocytosis, whereas nanoparticles with a size up to 500 nm are uptaken caveolae-mediated 
endocytosis [77]. However, they can also enter in the cells through a passive mechanism, by 
direct plasma membrane penetration [80]. 
The nanoparticle surface charge and hydrophobicity have influence on the nanoparticle 
uptake and/or the rate of transyctosis due to their influence on the pattern of proteins 
adsorbed from plasma. It is known that hydrophobic surfaces are rapidly opsonized followed 
by recognition by the reticuloendothelial system (RES), and higher internalization rates are 
usually associated with positively charged nanoparticles due to the negatively charged 
composition of the biological membranes. However, negatively charged nanoparticles can 
achieve efficient uptake rates after the adsorption or covalently coupling of targeting ligands. 
Still, the nanoparticle surface is not the only one to have influence on the successful brain 
delivery, but all the materials used in the nanoparticle formulation may influence their ability 
to deliver drugs across the BBB [77]. Thus, when designing the nanoparticle it is essential to 
give attention the surface materials chosen, but also to the core materials. 
In Table 2.3 are resumed some of the studies of encapsulation of therapeutic drugs in 
nanoparticles for targeted brain delivery, mainly for the treatment of PD and AD. The 
majority is trying to encapsulate drugs that are already used in the treatment, however some 
recent studies are using antioxidants and growth factors as new rising therapies that can 
prevent the progress of the disease or even reverse it.  
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Table 2.3 – Studies published using drug brain delivery systems, mainly for the treatment of 
PD and AD. The studies are divided by type of therapeutic drug used, material, targeting 
ligand and administration route (systemic or local). GDNF: Glial cell line-derived neurotrophic 
factor, BDNF: Brain-derived neurotrophic factor, VEGF:  Vascular endothelial growth factor.  
Therapeutic Drug Material 
Targeting 
Ligand 
Administration 
Route 
Model Ref. 
Dopamine 
Chitosan nanoparticle - Intraperitoneal In vitro [85] 
Molecular carrier 
Amino acid 
derivates 
Intraperitoneal - [86] 
Alginate scaffold 
embedding stable D-
loaded celulose acetate 
phthalate nanoparticle 
- Local 
Healthy 
Sprague-Dawley 
rats 
[87] 
Liposome - - In vitro [88] 
Succinyl Dopamine 
Quantum 
rods/amphiphilic 
polymer/PEG 
Galactose Local In vitro [89] 
GDNF 
PLGA nanoparticle - Local 
6-OHAD rat 
model 
[90] 
Lactoferrin-modified 
nanoparticle 
- -  [44] 
PAMAM/PEG nanoparticle Lactoferrin Intravenous 
Rotenone rat 
model 
[91] 
GDNF fused with 
collagen binding 
peptide 
PLGA/Collagen 
nanoparticle 
- Local In vitro [92] 
GDNF and BDNF 
PLGA microparticle within 
a PEG-based hydrogel 
- Local In vitro [93] 
GDNF and VEGF PLGA nanoparticle - Local 
6-OHAD rat 
model 
[94] 
Neurotrophin-3 and 
MIAMI stem cells 
PLGA microparticle with a 
biomimetic surface 
- Local 
6-OHAD rat 
model 
[95] 
Plasmic GDNF 
DNA compacted by 
polycations to form 
colloidally stable NP 
- Local 
6-OHAD rat 
model 
[96] 
Sialic acid 
Poly(N(2-hydroxypropyl) 
methacrylamide) 
- Local 
6-OHAD rat 
model 
[97] 
Levodopa-α-lipoic 
acid 
PLGA microparticle - Subcutaneous - [98] 
Levodopa methyl 
ester and 
benserazide 
(decarboxylase 
inhibitor) 
PLGA nanoparticle - Subcutaneous 
6-OHAD rat 
model 
[99] 
Polymeric nanoparticle - - 
LDA-stimulated 
dyskinetic rat 
model 
[100] 
Levodopa 
Chitosan nanoparticle 
thermoreversible to gel 
- Intranasal - [101] 
Liposome-PEG Chlorotoxin - In vitro [102] 
Rotigotine (agonist) PLGA microparticle - Intramuscular 
6-OHAD rat 
model 
[103] 
Apomorphine 
(agonist) 
PLGA microparticle - - - [104] 
Tripalmitin hydrogenated 
soybean 
phosphatidylcholine solid 
lipid nanoparticle 
- Oral 
6-OHAD rat 
model 
[105] 
Ropinirole (agonist) Nanoemulsion - Transdermal 
6-OHAD rat 
model 
[106] 
Bromocriptine 
(agonist and 
antioxidant) 
Chitosan nanoparticle - Intranasal 
Haloperidol rat 
model 
[107] 
Solid lipid nanoparticle - - - [108] 
Tempol 
(antioxidant) 
PLGA microparticle 
Ab OX-26 
Transferrin 
receptor 
- In vitro [109] 
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Rasagiline (MAO B 
inhibitor) 
PLGA nanoparticle - Intraperitoneal 
Rotenone rat 
model 
[110] 
Urocortin 
PEG-PLGA nanoparticle Lactoferrin Intravenous 
6-OHAD rat 
model 
[111] 
Lactoferrin-modifed 
nanoparticle 
- - - [44] 
PEG-PLGA nanoparticle Odorranalectin Intranasal 
6-OHAD rat 
model 
[112] 
Nerve growth 
factor 
Poly butylcyanocrylate 
nanoparticle 
Polysorbate-80 Intravenous MPTP rat model [113] 
Chelating ligands 
(CuAC, EDTA, 
histidine and ZnAc) 
Nanoliposome - - In vitro [114] 
Curcumine PLGA nanoparticles Tet-1 protein - - [115] 
Bromocriptine 
Tristearin/tricaprin 
nanostructures-solid lipid 
nanoparticle 
- - 
6-
hydroxydopamin
e hemilesioned 
rat model 
[116] 
Phosphatidic acid Nanoliposome Apoliprotein E - hCMEC/D3 cells [117] 
 
2.4.1 - Solid lipid nanoparticles 
Solid lipid nanoparticles (SLN) are a stable lipid-based nanoparticles composed by a solid 
hydrophobic lipid core where the therapeutic drug can be dissolved or dispersed (Figure 2.6). 
However, SLN are also feasible of incorporating hydrophilic drugs on their surface. These 
nanoparticles are made of an oil/water emulsion with lipids that are solid at room 
temperature and body temperature [118]. Their size is between 40 to 200 nm providing them 
the ability to cross tight endothelial cells of the BBB, escape from the reticulo-endothelial 
system (RES), and thus bypass liver and spleen filtration. In addition, the synthesis of these 
nanoparticles is cost effective, have excellent reproducibility and avoid the use of organic 
solvents [36].  
Besides having all the requirements described on the last section, SLN formulations are 
stable for approximately 3 years and the controlled drug release can be made to last several 
weeks. Triglycerides, fatty acids and waxes are examples of lipid used in the synthesis of SLN 
[84, 108]. 
Figure 2.6 – Schematic representation of a solid lipid nanoparticle. 
 
2.4.2 - Functionalization 
After intravenous injection, the nanoparticles are rapidly opsonized and cleared from the 
blood stream by the macrophages of the RES which are mainly localized in the liver and 
spleen [77, 82]. However, the blood circulation time of the nanoparticle can be prolonged by 
modification of the nanoparticle surface with surfactants or by covalent attachment of 
hydrophilic surfactants, such as polysorbates or polyethylene glycol (PEG) chains to the core 
polymer. Thus, the mass of drug delivered to the brain is proportional to the BBB 
permeability coefficient and the area under curve plasma concentration versus time [77]. 
Nanoparticles as Dug Delivery Systems 21 
 
 
 
Besides increasing the blood circulation time, PEG grants steric stabilization of the 
nanoparticle surface, allowing the attachment of ligands (e.g. antibodies, proteins or 
aptamers) capable of binding to BBB nutrient transport systems or internalizing receptors 
[84]. It is known that the ligands attached to the nanoparticle may increase the elimination 
rate by the RES, however the coverage of the nanoparticle with PEG reduces this effect [83]. 
The functionalization of the nanoparticle by covalent conjugation of various ligands can 
be used to target specific tissues, like the brain, enhancing the bioavailability of a drug, that 
otherwise was not able to cross the BBB, in that specific locus. Moreover, the 
functionalization of the nanoparticle surface can improve the crossing through the BBB by 
allowing an electrostatic interaction with the luminal surface of the BBB. This can be 
achieved by conferring a positive charge to the nanoparticles surface through 
functionalization with positively charges molecules. Thus, nanoparticles can be 
multifunctional and have several properties like drug delivery, targeting and diagnosing 
capabilities [7]. 
The selection of the ligands is extremely critical since the receptor should be 
preferentially expressed at the BBB, but ideally it should be brain specific in order to reduce 
potential side-effects and increasing transport efficiency [83]. Also, the natural saturation of 
the receptor must be considered to avoid competition with the natural ligand [84].  Some 
possibilities of molecular and cellular targets that can be focus for drug delivery therapy for 
PD are α-synuclein protein, leucine-rich repeat serine/threonine protein kinase 2 and the 
parkin protein, and for AD could be for example molecular targets that can act on α-, β-, and 
γ-synuclein peptides [40]. 
If a fluorescent probe is conjugated with the nanoparticle targeted to a PD or an AD 
biomarker it is possible to diagnose and follow the progress of these diseases. The copulation 
of this property with the simultaneous ability of delivering drugs is denominated theranostic 
[7]. 
Figure 2.7 is a representation of a nanoparticle where the drug is both encapsulated in 
the core and conjugated at the surface. Here are represented the vast kind of molecules that 
can be functionalized at the nanoparticle surface with the objective of targeting the brain 
(antibody, peptide, aptamers and cationic molecules), avoid the RES (PEG) and imaging 
purposes (fluorescent probe) [84].  
 
Figure 2.7 – Representation of a multifunctionalized nanoparticle with drugs (encapsulated in 
the core or conjugated at the surface), brain targeting molecules (antibodies, peptides, 
aptamers and cationic molecules), PEG and a fluorescent probe. Adapted from [84].   
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2.6.1 - Monoclonal antibodies 
The transferrin receptor (TfR) is expressed at a high level in the brain capillary 
endothelium, thus the targeted delivery of therapeutic compounds to it allows a greater 
therapeutic outcome [109]. However, transferrin is not an ideal TfR-targeting ligand due to 
the competition with the transferrin present in the bloodstream, leading to the saturation of 
these receptors [119, 120]. In order to overcome this problem, antibodies against the 
transferrin were developed, such as the OX-26 antibody [121].  
2.5 - Resveratrol as a potential therapy for neurologic diseases 
Resveratrol (3,5,4’-trihydroxystilbene) is a natural polyphenolic flavonoid, which can be 
found in nature as both cis and trans isomers, being the last considered to be the most 
abundant and biologic active. Several effects have been related with the intake of 
resveratrol, such as anti-carcinogenic, anti-inflammatory, anti-obesity and heart/brain 
protective effects (modulation of nitric oxide biosynthesis and activity) [6]. The 
neuroprotective effects of resveratrol in neurological disease, such as AD and PD, is related to 
the protection of neurons against oxidative damage and toxicity (due to ROS production), and 
to the prevention of apoptotic neuronal death [6, 51]. 
Figure 2.8 – Chemical structure of resveratrol. 
 
However, after intravenous injection, resveratrol is rapidly absorbed, metabolized into 
both glucuronic acid and sulfate conjugations of the phenolic groups in the liver and intestinal 
epithelial cells (within less than 2 hours), which are eliminated posteriorly [49].Thus, 
resveratrol has low bioavailability, limiting its biological and pharmacological benefits. It also 
has poor water solubility and is chemical instable, being degraded by isomerization when 
expose to elevated temperatures, pH changes, UV light or certain types of enzymes [6]. 
Furthermore, resveratrol has the ability of mimicking the healthy benefits of calorie 
restriction, also called dietary restriction, which is known that it leads to the stimulation of 
stress proteins and to the increase of the organism’s defense mechanisms [51]. 
Consequentially, this effect enhances the longevity of the organisms, but also protects the 
organism from stress. However, long-term effects of this treatment on neurodegenerative 
diseases were not studied yet, and the short-term adverse effects includes infertility, 
menstrual irregularities, hypertension, loss of libido, loss of strength and stamina, slower 
wound healing, depression and even irritability [49].  
Resveratrol can be found in the seeds and skins of grapes, red wine, mulberries, peanuts, 
rhubarb and in several other plants [51]. It’s concentration in the skin and seeds of grapes is 
approximately 50-100 ug per gram, corresponding to 5-10% of their biomass, nonetheless it 
varies considerably on different grape vine cultivars [6, 51]. This fact is associated with the 
French Paradox, which is refers to the beneficial effects of a moderate consumption of red 
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wine. Besides resveratrol, both red wine and purple grapes (specially the skin and seeds) 
contain several flavonoids, such as quercetins, catechins, gallocatechins, procyanidins, and 
prodelphidins [49]. 
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Chapter 3  
Materials and methods 
3.1 - Materials 
For the nanoparticles synthesis, trans-resveratrol (more than 99% pure) and polysorbate 
80 (Tween® 80) were purchased from Sigma-Aldrich (St Louis, MO, USA), the solid lipid 
cetylpalmitate was provided by Gattefossé (Nanterre, France). The grape’s skin and seed 
extracts were provided by BioPolyphenols (DoisPortos, Portugal) and Monteloeder (Elche, 
Spain), respectively. 
For the nanoparticle functionalization, 1,2-Distearoyld-sn-Glycero-3-
Phosphoethanolamine -N-maleimide(polyethylene Glycol)2000 was purchased from Avanti 
Polar Lipids (Alabaster, Alabama, USA), and the monoclonal antibodies for transferrin BBB 
receptors, OX-26 mAb, were purchased from AbD Serotec (Kidlington, UK). For the ELISA assay 
the human transferrin receptor peptide was bought from Abcam® (Cambridge, UK) and the 
secondary antibody, Goat anti-mouse IgG (H+L), was purchased from Thermo Fisher Scientific 
(Waltham, MA USA). 
For the grids preparation for morphological analysis on TEM, uranyl acetate was 
purchased from Electron Microscopy Sciences (Hatfield, PA, USA). 
The α-synuclein human and the β-amyloid (1-42) human, for the kinetics studies were 
purchased from Sigma-Aldrich (St Louis, MO, USA) and GenScript (Piscataway, NJ, USA), 
respectively. Moreover, the Thioflavin T was provided by Sigma-Aldrich (St Louis, MO, USA). 
The water used in all experiments during this project was purified water by Ultra-pure 
water system (Milli-Q RG), and was obtained from a reverse osmosis process. 
3.2 - Methods 
3.2.1 -  Solid lipid nanoparticles preparation 
The method used for the nanoparticle synthesis is a compromise between the high shear 
homogenization method and the ultrasonication method, and it is represented in Figure 3.1. 
Hence, it is possible to produce particles with a micrometer size by the first method, and 
then, reduce their size to the nanometer size range by the second method. 
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Figure 3.1 - Scheme of the preparation method of the solid lipid nanoparticles. 
  
The lipid phase, containing DSPE-PEG(2000)maleimide, the cetylpalmitate (solid lipid), 
the stabilizer polysorbate 80 and the drug to be encapsulated (0, 2, 5, 10 or 15 mg) was 
melted at 70ºC, which is above the lipid’s melting point. The melted lipid was then dispersed 
in ultrapure water, at the same temperature, by high-speed stirring in an Ultra-Turrax T25 
(Janke and Kunkel IKA-Labortechnik, Staufen, Germany) followed by sonication (70% 
amplitude) using a Sonics and Materials Vibra-CellTM CV18 (Newton, CT, USA). The 
nanoemulsion was let cooling at room temperature to allow the crystallization of the lipid and 
consequent formation of the solid lipid nanoparticles. 
 
 
Table 3.1 – Chemical structure of the lipids used for the synthesis of the solid lipid nanoparticles. 
Name Structure 
Cetylpalmitate 
 
Polysorbate 80 
 
DSPE-PEG(2000) 
Maleimide:  
1,2-distearoyl-sn-
glycero-3-
phosphoethanolamine-N-
(maleimide(polyethylene
glycol)-2000) 
 
 
 
 
 
Resveratrol 
loaded lipid 
nanoparticles 
Sonication 
Pre-imulsion 
by ultra-
turrax 
Adition to a 
hot aqueous 
surfactant 
mixture 
Melting of the 
mixture lipid 
plus the 
resveratrol 
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The parameters of both techniques were previously optimized to establish the best 
conditions for the production of a stable formulation with an average size of less than 200 
nm. The final parameters chosen were a high shear homogenization of 2 minutes at 12000 
rpm, and a 15 minutes sonication at intensity of 70%.  
Three different compounds were encapsulated on the lipid nanoparticles: pure 
resveratrol, grape’s seeds and skin (with and without centrifugation).  
The formulations were storage for at least 1 month protected from light, at room 
temperature, and they were characterized periodically in order to access the stability of the 
nanoparticles. Moreover, the effect of different drug/lipid ratio was assessed. 
 
 
3.2.2 - Conjugation of the antibodies 
Covalent coupling methods for attaching the antibodies at the PEG terminus by using 
functionalized PEG with a chemically reactive end-group were applied. For the maleimide-
mAb conjugation, the target was activated by a twenty times molar excess of Traut’s reagent 
(2-iminothiolane hydrochloride, MW 137.73, Sigma-Aldrich). Moreover, a drop of EDTA 
(ethylenediaminetetraacetic acid, MW 292.40, Sigma-Aldrich) 0.28 M was added to prevent 
metal catalysed oxidation of sulfhydryl groups. The unreacted EDTA/2-iminothiolane 
complexes were removed through application of a size exclusion chromatography using a 
Sephadex column PD-Minitrap G25 (GE Healthcare). After the conjugation with the 
antibodies, samples were incubated at room temperature for 1 hour and then at 4 ºC 
overnight. The antibodies were added to the solid lipid nanoparticles at a molar ratio of 1:1 
between antibodies and functionalized PEG. 
The affinity of the conjugated solid lipid nanoparticles for transferrin (TfR) was analysed 
by ELISA. For this, the surface of a 96-well plate (flat-bottom Nunc MaxiSorp®) was coated 
with TfR during 1 hour at 37 ºC. The plate was then blocked with BSA (bovine serum albumin, 
~66 kDa) and incubated for another hour at 37 ºC, followed of addition of the nanoparticles to 
each well. After incubation and subsequent washing, the secondary antibody, which was 
conjugated with peroxidase, was let react during 45 minutes at room temperature. The 
reveal solution was composed by citric acid (MW 210.14, Sigma-Aldrich), ABTS (2,2′-azino-
bis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt, MW 548.68, Sigma Aldrich) and 
H2O2 (hydrogen peroxide solution, MW 34.02, Sigma Aldrich), and the absorbance spectrum of 
each well was read at 405 nm using a Biotek Synergy 2 spectrometer. Furthermore, 
nanoparticles without being conjugated were used as a negative control. 
 
3.2.3 - Nanoparticles size 
The nanoparticles size was measured by dynamic light scattering (DLS). DLS allows the 
determination of particle size and size distribution in dispersions (polydispersity index, PI). 
The results are based on fluctuations of the light scattered intensity as a function of time, 
which are directly related to the Brownian motion of the solute and can be related with their 
diffusion coefficient [122].  Therefore, the SLN size of monodisperse nanoparticles can be 
calculated using the Stokes-Einstein equation [123]: 
𝑅𝐻 =
𝑘𝑇
6𝜋𝜂𝐷
                     (3.1) 
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where, RH is the hydrodynamic radius, k is the Boltzman constant, T is the temperature, η is 
the viscosity of the solvent and D is the diffusion coefficient of the nanoparticles. 
Samples were diluted (1:200) in ultrapure water to achieve a suitable scattering 
intensity, which is translated into an average count rate between 100 and 500 kcps. The 
formulations were analysed at 25ºC and both size and PI were calculated through the average 
of 10 runs, in triplicate.  
 
3.2.4 - Zeta potential 
Zeta potential of the lipid nanoparticles was measured by electrophoretic light scattering 
(ELS). It is known that nanoparticles in suspension attract ions to their surface, forming an 
electrical double layer at the nanoparticle surface (an inner layer where ions are strongly 
adsorbed to the surface, and an outer layer where ions diffuse more freely). Zeta potential is 
defined as the electric potential that exists in the diffuse boundary of the nanoparticle 
(boundary of the outer layer with the bulk solution). It can be calculated using Henry’s Law  
[124]: 
𝑈𝐸 =
2𝜀𝑧𝑓(𝑘𝑎)
3𝜂
                  (3.2) 
where, UE is the electrophoretic mobility, z is the zeta potential, f(ka) is the Henry’s function 
and η is the viscosity coefficient. Zeta potential is an indicator of the stability of the 
nanoparticle suspension [125]. 
Samples were diluted (1:200) in ultrapure water, transferred to folded capillary cells from 
Malvern (Worcestershire, UK) and their zeta potential was obtained by the average of 3 
measurements (each one with 12 runs) using a ZetaSizer Nano ZS (Malvern Instruments, 
Worcestershire, UK). 
 
3.2.5 - Morphologic analysis 
The nanoparticle morphology was characterized by transmission electron microscopy 
(TEM). In this technique, an electron beam hits the sample and part of it is transmitted 
through the sample, reaching to a phosphor screen where the image is formed. The 
differences on the image contrast are dependent of the amount of electrons that did not 
interacted with the sample and were able to pass through it. Therefore, darker regions are 
due to the few electrons that were transmitted as a result of higher thickness or density of 
the sample, and brighter regions results of a higher electron transmission [122]. 
Nanoparticles samples were prepared on 400 mesh Formvar/Carbon copper grids (Agar 
Scientific, Essex, UK). For this, 5 µL of each sample was placed on the mesh and let to absorb 
for five minutes. The negative staining (2% filtered aqueous solution of uranyl acetate) was 
let react for 45 seconds, the excess was removed and the grid was let drying. The 
morphological analysis was accessed on a JEOL JEM-1400 TEM at an accelerating voltage 80kV 
(Tokyo, Japan). 
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3.2.6 - Determination of entrapment efficiency 
The entrapment efficiency (EE) of the compounds was determined through the difference 
between the amount used in the formulation synthesis and the amount that remained free in 
the aqueous phase, as follows: 
%𝐸𝐸 = 1 −
𝑈𝑛𝑒𝑛𝑡𝑟𝑎𝑝𝑝𝑒𝑑 𝑑𝑟𝑢𝑔
𝑇𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔
× 100                    (3.3) 
Samples of the different formulations were diluted in ultrapure water (1:200), transferred 
into Amicon® Ultra Centrifugal Filters (Merck Millipore, Billerica, MA, USA), and centrifuged 
using a Allegra® X-15R Centrifuge (Beckman Coulter, Pasadena, CA, USA) during 25 minutes at 
4300 rpm. Afterward, the free drug present in the supernatant was collected and quantified 
using a V-660 spectrophotometer (Jasco, Easton, MD, USA) at 200-600 nm.  
 
3.2.7 - Determination of the yield  
The yield was determined by calculating the weight difference of the samples before and 
after filtration (Equation 3.4). In order to do this, two set of samples, one filtrated and the 
other non-filtrated, were let dry out and the remaining lipid was weighted. This assay allows 
knowing an approximation of the quantity of nanoparticles lost with filtration. 
𝑌𝑖𝑒𝑙𝑑 (%) =
𝑟𝑒𝑚𝑎𝑖𝑛𝑖𝑛𝑔 𝑙𝑖𝑝𝑖𝑑 𝑎𝑓𝑡𝑒𝑟 𝑓𝑖𝑙𝑡𝑟𝑎𝑡𝑖𝑜𝑛
𝑟𝑒𝑚𝑎𝑖𝑛𝑖𝑛𝑔 𝑙𝑖𝑝𝑖𝑑 𝑏𝑒𝑓𝑜𝑟𝑒 𝑓𝑖𝑙𝑡𝑟𝑎𝑡𝑖𝑜𝑛
× 100         (3.4) 
     
3.2.8 - Fluorescence measurements and Thioflavin T binding assay 
Interaction of the nanoparticles with α-synuclein and amyloid-β was evaluated through 
the Thioflavin T (ThT) binding assay. ThT is a common amyloid dye, which binds rapidly to to 
amyloid fibril structures, have a strong fluorescence emission. Furthermore, the intensity of 
the fluorescence is proportional to the quantity of amyloid fibrils [126].  
A ThT sock solution was prepared in phosphate buffer saline (PBS) or sodium phosphate 
buffer at the concentration of 0.8mg/mL, and a ThT working solution was prepared by 
diluting 1mL of the stock solution in 50mL of buffer. Samples containing α-synuclein (final 
concentration of 20 µM) in sodium phosphate buffer, and samples containing amyloid-β (final 
concentration of 25 µM) in PBS, were filtered, diluted and added to the ThT working solution 
immediately after preparation. The samples were placed on a 96-well plate (Nunclon Delta 
Surface) and the intensity was measured on a Biotek Synergy 2 fluorescence spectrometer 
(Winooski, USA) after stirring 30 seconds every 15 minutes during 10 days. The temperature 
was maintained constant at 37ºC.  
 
 
3.2.9 - Statistical analysis 
The statistical analysis was performed using SigmaPlotTM software (v 13.0; Systat 
Software, CA, USA). The measurements were at least three times and data were expressed as 
mean ± SD. Data were analysed using two-way analysis of variance (two-way ANOVA), 
followed by Holm-Sides and Tukey tests. A P value of 0.05 was considered statistically 
significant. 
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Chapter 4  
Results and discussion 
4.1 - Physicochemical characterization of solid lipid 
nanoparticles  
Unloaded solid lipid nanoparticles were synthesized by the hot homogenization technique 
and characterized.  The mean size of the unloaded nanoparticles measured by DLS was 142 ± 
10 nm. This size corresponds to the required size for brain drug delivery [127].  
The PDI of the unloaded SLN was 0.12 ± 0.04 showing that the formulation has a 
monodisperse population.  
The zeta potential of the nanoparticles was -0.08 mV. In this case, the nanoparticles 
exhibited low electrostatic stabilization, but they still are stable. 
In order to choose the more favourable drug concentration for SLN, formulations with 
different concentrations of grape’s extracts (2, 5, 10 and 15 mg) were prepared and 
characterized according to their entrapment efficiency, average size and zeta potential. 
The grape’s extracts loaded-nanoparticles mean size is presented in Figure 4.2. All 
formulations showed a homogeneous size distribution with a mean diameter between 150 nm 
and 200 nm, except the nanoparticles loaded with centrifuged grape’s seeds, which achieve a 
mean size higher than the required size range. Although there was no statistically difference 
(P>0.05). 
 
 
Figure 4.1 – Mean size of the nanoparticles (skin, centrifuged skin, seeds and centrifuged seeds). All 
values represent the average and the standard deviation (n=3).  
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As the unloaded SLN, the zeta potential of the different extracts-loaded nanoparticles 
was almost neural, meaning that the encapsulation of these compounds did not have impact 
on the zeta potential (Table 4.1) as no statistically significance differences where observed 
between any of the formulations (P > 0.05). 
 
Table 4.1 - Zeta potential of the nanoparticles (skin, centrifuged skin, seeds and centrifuged seeds). All 
values represent the average (n=2).  
SLN 
Quantity of drug (mg) 
2  5 10 15 
Skin 0.07 0.18 -0.07 -0.34 
Centrifuged Skin -0.11 -0.16 -0.09 0.01 
Seeds -0.17 -0.06 0.35 -0.21 
Centrifuged Seeds -0.06 0.05 0.02 -0.02 
 
The encapsulation efficiency of each of these formulations is shown of Figure 4.2. 
Generally, the percentage of encapsulation was higher than 60%. It is also possible to observe 
that increasing the extract concentration, the entrapment efficiency decreases as it would be 
expected. However, these differences on the percentage of drug encapsulated were not 
significant (P>0.05). The main natural resource of resveratrol is the grape, but its 
concentration present on the extracts is very low (20 mg/kg of dry skin and 6.8 mg/kg of dry 
seed) [128]. Therefore, calibration curves (Annex A) were made for all the compounds used, 
since the percentage of resveratrol present in the grape’s extracts is too low to be detected 
by absorbance without being affected by others compounds present in the extracts that also 
can absorb at the same wavelength [128].  
 
 
Figure 4.2 – Entrapment efficiency of the nanoparticles (skin, centrifuged skin, seeds and centrifuged 
seeds) in percentage of compound encapsulated (calculated through the calibration curve of each drug: 
Annex A). All values represent the average and the standard deviation (n=2). 
 
Taking the previous results in account, the final drug concentration chosen was 10 mg. 
The next step was to synthetize resveratrol-loaded nanoparticles and proceed to their 
characterization and other studies. 
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In Table 4.2 are presented the average size, polidispersity index, zeta potential and 
entrapment efficiency of the nanoparticles synthetised with 10 mg of drug and of the 
unloaded nanoparticles. The formulations appeared white (unloaded and resveratrol), beige 
(seeds and centrifuged seeds) or pink (skins and centrifuged seeds) and had low viscosity. 
All of the formulation showed a homogeneous size distribution, with a a size inferior to 
200 nm with the PI inferior to 0.2, indicating that the formulations have a good 
monodispersity distribition, with low variability and no aggregation.  
 
Table 4.2 – Characterization of the lipid nanoparticles (10mg of drug). All values represent the average 
and the standard deviation (n=3).  
SLN 10mg Size (nm) 
Polidispersity 
Index 
Zeta 
Potential 
(mV) 
Entrapment 
Efficiency 
(%) 
Unloaded 142 ± 10 0.12 ± 0.04 -0.08 - 
Resveratrol 176 ± 24 0.16 ± 0.10 0.17 94 ± 9 
Grape’s skin 182 ± 6 0.11 ± 0.04 -0.07 93 ± 6 
Centrifuged grape’s skin 178 ± 13 0.11 ± 0.04 -0.09 86 ± 5 
Grape’s seeds 188 ± 11 0.13 ± 0.04 0.34 95 ± 2 
Centrifuged grape’s seeds 194 ± 21 0.11 ± 0.04 0.02 94 ± 6 
 
There was no significative differences on the zeta potential of all formulations, also 
meaning that the encapsulation of the different compounds did not altered the surface 
charge of the nanoparticles. 
The entrapment efficiency of all the formulations synthesized achieved an high 
percentage value around 90%, suggesting that the lipid nanoparticles are a suitable system for 
the incorporation of both resveratrol and grape’s extracts. This is confirmed by the fact of 
that resveratrol has a lipophilic nature, thus its preferential localization should be in the 
nanoparticle’s core. The same happens with the grape’s extracts, even though they are 
constituted by hydrophilic and lipophilic compounds, the extracts were successfully  
encapsulated in the SLNs. Furthermore, no significant differences were found between the 
different nanoparticles (P > 0.05). 
4.1.1 - Morphology 
The morphology of the lipid nanoparticles was observed by TEM (Figure 4.3). The images 
revelled that generally the nanoparticles were almost spherical and with an uniform shape 
with smooth surfaces. TEM allowed confirming the sizes previously measured by DLS. 
Moreover, it is possible to observe that the nanoparticles shape did not seem to be altered 
when loaded with different compounds. Some aggregation was visible (Figure 4.3: C and E), 
however it could be due to the dilution rate of the formulation. 
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Figure 4.3 – TEM images of unloaded SLN (A, B), SLN resveratrol (C, D), SLN skin (E, F), SLN centrifuged 
skin (G, H), SLN seeds (I, J) and SLN centrifuged seeds (K, L). Samples were diluted at a ratio of 1:100. 
Scale bar: 500 nm.
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4.2 - Process yield 
The process yield of the nanoparticles filtered through a 200 nm filter is 48±6%, which 
means that half of the nanoparticles constituents (lipids and/or drug) were lost during this 
process. 
4.3 - Conjugation of the antibodies  
For this experiment two types of lipid nanoparticles were developed. As a control, 
nanoparticles without conjugation with antibodies (mAb OX-26) were synthetised. 
The binding of the mAb to the nanoparticles was determined by ELISA (Figure 4.4). 
Significantly higher absorbance at 405 nm was observed in the nanoparticles conjugated with 
mAbs when compared with the negative control and the nanoparticles without conjugation. 
Therefore, the antibody used demonstrate bioactivity for the transferrin receptor. 
It is also important to refer that the thiolation of the mAbs does not interfere with their 
binding site [129], however the maleimide group can be hydrolysed when in contact with 
water, so it is highly recommended to conjugate the mAbs immediately after the nanoparticle 
synthesis. 
 
 
 
Figure 4.4 – ELISA assay results of the negative (water) and positive control (OX-26), nanoparticles with 
and without conjugation with OX-26. All values represent the average and the standard deviation (n=2). 
 
After conjugation, the nanoparticles size increased around 60 nm with no significance (P > 
0.05) on the SLN skin, resveratrol and unloaded, and with significance on the SLN centrifuged 
skin, seeds and centrifuged seeds (P < 0.05). The size increase of the nanoparticles is an 
indicator if an efficient conjugation since the diameter of the globular antibody is 
approximately 15 nm [130]. However, and exaggerated increase could mean aggregation of 
the nanoparticles with is not desirable.  
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Figure 4.5 – Comparison between the nanoparticles average size without and with antibodies. There are 
represented the sizes of SLN skin, SLN centrifuged skin, SLN seeds, SLN centrifuged seeds, SLN 
resveratrol and unloaded SLN. All values represent the average and the standard deviation (n=2).  
4.4 - Solid lipid nanoparticle stability 
After synthesis and after each month, the nanoparticle size was determined (Figure 4.6). 
Both average diameter and polidispersity index were used as an indication of nanoparticle 
aggregation and stability. For the majority of the formulations the average diameter 
increased during storage, however this increase was only statistically significant in few 
formulations when compared with the initial size (P < 0.05). Thus, although there was a slight 
increase of the size, it does not imply aggregation of the nanoparticles since the most of the 
nanoparticles still have less than 200 nm. 
  
Figure 4.6 - Effect of the storage (at room temperature) on the nanoparticle size loaded with 10 mg of 
different compounds (grape’s skin, grape’s centrifuged skin, grape’s seeds, grape’s centrifuged seeds or 
resveratrol) and on the unloaded nanoparticles. Both SLN resveratrol and unloaded SLN were only 
studied until 1 month of storage. All values represent the average and the standard deviation (n=3).  
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On Table 4.3 is represented the effect of the storage on the SLN zeta potential of the 
different formulations. Since the values are not significantly different from each other, it is 
possible to affirm that the nanoparticles steric stability has not been affected by the storage 
time neither the storage conditions. This stability is corroborated by the maintenance of the 
nanoparticles size observed before. 
 
Table 4.3 - Effect of the storage (at room temperature) on the nanoparticle zeta potential loaded with 
10 mg of different compounds (grape’s skin, grape’s centrifuged skin, grape’s seeds, grape’s centrifuged 
seeds or resveratrol) and on the unloaded nanoparticles. Both SLN resveratrol and unloaded SLN were 
only studied until 1 month of storage. All values represent the average (n=3).  
SLN 
Time of storage (months) 
0 1 2 
Unloaded -0.08 0.02 -0.07 
Resveratrol 0.19 0.02 -0.06 
Skin -0.07 -0.14 -0.02 
Centrifuged Skin -0.09 -0.04 -0.15 
Seeds 0.34 -0.005 -0.04 
Centrifuged Seeds 0.02 0.06 -0.09 
 
One parameter to access the stability of the different formulations is the entrapment 
efficiency. It is know that SLN have a highly organized matrix with a tendency to from perfect 
crystals over time, which can eventually lead to an expulsion of the drug during the storage. 
However, the results of entrapment efficiency shown on Figure 4.7 contradict this hypothesis, 
demonstrating that the nanoparticles studies were able to retain the initial amount of 
encapsulated drug at least during 2 months. Only in one formulation statistically significance 
differences where observed between the final and initial time of storage (P < 0.05).  
  
Figure 4.7 – Effect of the storage (at room temperature) on the nanoparticle entrapment efficiency 
loaded with 10 mg of different compounds (grape’s skin, grape’s centrifuged skin, grape’s seeds, 
grape’s centrifuged seeds or resveratrol) and on the unloaded nanoparticles. All values represent the 
average (n=3).  
This stability study shows that the lipid nanoparticles synthesized resulted in a stable 
nanocarrier, which can be used as a controlled-release strategy for brain targeted delivery of 
both resveratrol and grape’s extracts (skin and seeds). 
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4.5 - Effect of the loaded solid lipid nanoparticles on the α-
synuclein and amyloid-β aggregation 
In order to know how the different nanoparticles interact with α-synuclein and amyloid-β, 
specifically to know it they are able to prevent and/or reduce the aggregation of these 
peptides, two kinetics studies were made. 
The results of the kinetic studies with amyloid-β are shown on Figure 4.8 (interaction with 
compounds) and Figure 4.9 (interaction with lipid nanoparticles). On Figure 4.8 is clear the 
both resveratrol and grape’s extracts were able to inhibit the aggregation of amyloid-β, being 
the inhibition more accentuated when it interacts with resveratrol. 
On the other hand, when these compounds are encapsulated it seems that the inhibition 
of the aggregation is diminished (Figure 4.9). This could be due to the difference of drug 
concentration on the different assays: the concentration of drug on the first one is the same 
as the theoretical concentration of the drug in the nanoparticles, without taking in account 
the yield of the filtering process. Moreover, is possible that the drug release did not achieve a 
considerable percentage of drug able to get out of the nanoparticles due to low degradation 
of the lipid nanoparticles. These results also shown that the unloaded nanoparticles acted as 
nucleus that promotes the aggregation of the amyloid-β peptide, since when both are 
incubated the value of fluorescence was higher than the amyloid-β incubated alone. 
On Figure 4.10 the results of the interaction of the different lipid nanoparticles with α-
synuclein peptide are presented. Although the formation of aggregates occurred, it is possible 
to notice a diminished fluorescence when the nanoparticles where incubated with the α-
synuclein, leading to the conclusion that the different compound did indeed inhibited the 
aggregation potential of the α-synuclein.  
Several studies indicate that the central region and the C-terminal tail of α-synuclein and 
amyloid-β are considered to have an important modulating role in the formation of pre-
oligomers [131-133], thus peptide binding with these regions can prevent the formation of 
aggregates. Additionally, different mechanisms could be involved in the interaction of 
amyloid aggregates with both resveratrol and grape’s extracts. Properties such as aromatic 
interactions, antioxidative activity, metal chelating and hydrogel binding can contribute to 
the inhibition of aggregates formation [134, 135].  
Furthermore, resveratrol can intervene in the natural development of neurodegenerative 
diseases, preventing further neuronal deterioration [136]. The same applies to the grape’s 
extracts, even if resveratrol is not the main constituent, its action results of synergic action 
of a mixture of many bioactive constituents, essentially polyphenols [134]. 
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Figure 4.8 - Kinetic study of the interaction of the free resveratrol and grape’s extracts with the 
amyloid-β peptide using Thioflavin T. 
Figure 4.9 – Kinetic study of the interaction of the loaded-nanoparticles (resveratrol and grape’s 
extracts) and unloaded-nanoparticles with the amyloid-β peptide using Thioflavin T. 
 
 
Figure 4.10 - Kinetic study of the interaction of the loaded-nanoparticles (resveratrol and grape’s 
extracts) and unloaded-nanoparticles with the α-synuclein peptide using Thioflavin T. 
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Chapter 5  
Concluding remarks and future 
perspectives 
Nowadays, neurodegenerative diseases are one of the major health problems in the world 
and, since there has been an increase of lifetime and aging of population, the number of 
neurodegenerative diseases also expected to increase in the near future. So it is clear the 
necessity of a new therapy for neurodegenerative diseases that affect the disease 
progression, rather than simply treating the symptoms. Nanotechnology has an important role 
on the development of an effective solution for the therapy of neurodegenerative disorders 
such as PD and AD through the drug delivery, neuroprotection or even though the 
regeneration of damaged neurons [7]. 
The use of nanoparticles to transport therapeutic drugs for both PD and AD, through non-
invasive administration by intravenous injection, is an alluring method to avoid the long-term 
side-effects and peripheral toxicity associated to the relatively toxic drugs. Also, the 
effective brain drug delivery by the use of nanoparticles may reduce the necessary drug 
dosage, and will lead to an improvement of the patient’s quality of life. Furthermore, they 
are able to transport a great variety of drugs across the BBB, including therapeutic drugs that 
were not used for treatment of these diseases due to their inability to cross this barrier in 
therapeutically effective concentrations [77]. However, it is necessary to give attention to 
the nanoparticle properties, like size, shape, geometry, charge, structure and composition, in 
order to guarantee the control of their fate in the in vivo environment [7]. 
In this work, the advantageous properties of both resveratrol and grape’s extracts have 
been exploited by its encapsulation in lipid nanoparticles. These nanoparticles were 
functionalized with OX-26 antibodies to target the blood-brain barrier. Stability studies were 
performed to access the use of these SLN as promising future drug delivery systems, and the 
results showed that the nanoparticles are stable for a minimum period of two months without 
functionalization. However, when the coupling of the antibodies happened, the stability of 
the systems was greatly diminished, indicating that the process needs to be optimized to 
avoid the aggregation of the nanoparticles. 
The interaction studies showed that the nanoparticles loaded with resveratrol or grape’s 
extracts delayed and reduce the aggregation of α-synuclein or amyloid-β. Moreover, the 
synthesized nanoparticles exhibit high encapsulation efficiencies of the compounds studied, 
even after storage. Overall, the solid lipid nanoparticles are a promising dynamic system for 
the targeted delivery of grape’s extracts, as a natural substitute of resveratrol, to the brain 
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in order to inhibit the formation of α-synuclein or amyloid-β aggregates, thus preventing, 
lowing the progression or even reverse both PD and AD. 
The next steps involve the study of the release profile of the encapsulated molecules in 
an environment that simulated the blood stream and in vitro studies with BBB-models to 
confirm their ability to cross this barrier. 
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Annex A  
Calibration Curves 
The calibration curves of the grape’s extracts were read at the wavelength of 278.5 nm 
and the extrapolations were made in mg of extract per mL of solution on a V-660 
spectrophotometer (Jasco, Easton, MD, USA). 
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Figure A.2 – Calibration curve of grape’s skin. 
Figure A.1 - Calibration curve of grape’s centrifuged skin. 
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Figure A.3 - Calibration curve of grape’s seeds. 
Figure A.4 - Calibration curve of grape’s centrifuged seeds. 
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The calibration curve for resveratrol was read at the wavelength of 305 nm on a V-660 
spectrophotometer (Jasco, Easton, MD, USA). 
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Figure A.5 - Calibration curve of resveratrol. 
